SVB Leerink analyst Andrew Berens maintains Merus (NASDAQ:MRUS) with a Outperform and raises the price target from $33 to $39.
Alpha Tau Announces Grant Of Expanded Radioactive License And Final Pre-Clinical Laboratory Regulatory Approval At Its Jerusalem Headquarters
Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the Israeli
